Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer

Persistence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor-positive (HR +) breast cancer

Abstract Purpose Extending adjuvant endocrine therapy (ET) beyond the standard 5 years offers added protection against late breast cancer recurrences in women with early-stage hormone receptor-positive (HR +) breast cancer. Little is known about treatment persistence to extended ET (EET) and the rol...

Full description

Bibliographic Details
Main Authors: Julia Foldi, Anastasia Tsagianni, Max Salganik, Catherine A. Schnabel, Adam Brufsky, G. J. van Londen, Lajos Pusztai, Tara Sanft
Format: Article
Language:English
Published: BMC 2023-06-01
Series:BMC Cancer
Subjects:
Breast Cancer Index
Extended adjuvant endocrine therapy
Endocrine therapy adherence
Online Access:https://doi.org/10.1186/s12885-023-11104-w

Internet

https://doi.org/10.1186/s12885-023-11104-w

Similar Items